Campbell & CO Investment Adviser LLC Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Campbell & CO Investment Adviser LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 53.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,182 shares of the pharmaceutical company’s stock after buying an additional 764 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Vertex Pharmaceuticals were worth $759,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. OFI Invest Asset Management purchased a new position in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. ST Germain D J Co. Inc. purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $26,000. Marquette Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $27,000. Compass Wealth Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Cornerstone Planning Group LLC purchased a new position in shares of Vertex Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 90.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on VRTX. Barclays raised their price target on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Sanford C. Bernstein lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Wells Fargo & Company lifted their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $412.62.

Get Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Trading Down 0.0 %

Shares of Vertex Pharmaceuticals stock opened at $422.91 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.89. Vertex Pharmaceuticals Incorporated has a 1 year low of $283.60 and a 1 year high of $448.40. The company has a market capitalization of $108.98 billion, a P/E ratio of 30.45, a P/E/G ratio of 2.31 and a beta of 0.36. The business has a 50 day moving average price of $411.25 and a 200 day moving average price of $374.82.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm posted $3.33 EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $419.07, for a total value of $2,785,977.36. Following the completion of the transaction, the chairman now directly owns 2,423 shares in the company, valued at approximately $1,015,406.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.

Featured Articles

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.